Publicacións en colaboración con investigadores/as de Hospital do Meixoeiro (23)

2023

  1. Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study

    Clinical and experimental rheumatology, Vol. 41, Núm. 10, pp. 2105-2114

2016

  1. Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 2, pp. 348-355

2015

  1. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome

    Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216

2014

  1. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: Analysis of 921 spanish patients (GEAS-SS registry)

    Rheumatology (United Kingdom), Vol. 53, Núm. 2, pp. 321-331

2013

  1. Discrepancy between stress electrocardiographic changes and nuclear myocardial perfusion defects in the prognostic assessmentof patients with chest pain

    Revista Portuguesa de Cardiologia, Vol. 32, Núm. 10, pp. 761-768

  2. Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome

    PLoS ONE, Vol. 8, Núm. 9

  3. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

  4. Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction

    European Journal of Pharmaceutical Sciences, Vol. 49, Núm. 4, pp. 512-518

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Evidence for a role of advanced glycation end products in atrial fibrillation

    International Journal of Cardiology, Vol. 157, Núm. 3, pp. 397-402

  3. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report

    Cardiovascular Diabetology, Vol. 11

2011

  1. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of seattle heart failure score

    American Journal of Cardiology, Vol. 107, Núm. 6, pp. 938-944

2010

  1. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels

    European Journal of Heart Failure, Vol. 12, Núm. 10, pp. 1092-1100

2009

  1. Utilidad clínica de la 18FDOPA-PET en trastornos del movimiento. Una revisión sistemática

    Revista Espanola de Medicina Nuclear, Vol. 28, Núm. 3, pp. 106-113

2008

  1. A "new" automated bolus technique for continuous popliteal block: A prospective, randomized comparison with a continuous infusion technique

    Anesthesia and Analgesia, Vol. 107, Núm. 4, pp. 1433-1437

2007

  1. Effectiveness of 123I-ioflupane (DaTSCAN©) in the diagnosis of Parkinsonian syndromes. A systematic review

    Revista Espanola de Medicina Nuclear, Vol. 26, Núm. 6, pp. 375-384

2006

  1. Actividad asistencial en las consultas externas de las unidades de reumatología de Galicia

    Reumatologia Clinica, Vol. 2, Núm. 5, pp. 239-246

  2. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: A cross-sectional study

    Cardiovascular Diabetology, Vol. 5

2004

  1. Oxidation of methionine residues in the prion protein by hydrogen peroxide

    Archives of Biochemistry and Biophysics, Vol. 432, Núm. 2, pp. 188-195

2003

  1. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

    Medical Oncology, Vol. 20, Núm. 1, pp. 37-43